Amarillo Biosciences: IND for pulmonary fibrosis passes FDA review, other drug trials on track

By Lisa Kerner

Charlotte, N.C., Aug. 11 - Amarillo Biosciences, Inc. said its Investigational New Drug application for idiopathic pulmonary fibrosis (IPF) has successfully passed the Food and Drug Administration's 30-day review process.

As a result, the company's 60-patient phase 2 study to test low-dose oral interferon as a treatment of chronic cough in IPF patients is slated to begin in the fourth quarter.

In other news, the Amarillo said it has launched an 80-patient phase 2 study of oral warts in HIV, with enrollment to begin in September.

The company's phase 2 study of Behcet's disease has enrolled 26 of 90 targeted patients, with enrollment to conclude by year-end. Study results are expected by mid-2007, according to a company news release.

Amarillo said it will begin selling its new human dietary supplement, derived from cattle and designed to boost the immune system, in early 2007.

In addition, the company announced a private placement of 1.2 million shares of restricted stock for $660,000 to fund its IPF and oral warts studies.

Amarillo has raised a total of $1.5 million through the sale of restricted shares in 2006.

Amarillo, operating in global partnership with the Hayashibara Group, is an Amarillo, Texas-based biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.